Thomson Reuters News & Insight
Featured Content from WESTLAW
Beginning in June, Thomson Reuters News & Insight content will be available exclusively on WestlawNext®, as part of its Practitioner Insights offering. On June 21, the Thomson Reuters News & Insight website, iPhone® app and newsletters will be discontinued. See Frequently Asked Questions to learn more.

New York Legal

  •  
  •  

More ripples from 2nd Circuit ruling on MBS class action standing  read more »

Supreme Court to resolve circuit split on timing of appeals  read more »

MBS put-back plaintiffs: Be careful how you draft complaints  read more »

Marketing Popup

1st Circuit joins debate over leftover class settlement funds

4/26/2012 COMMENTS (0)

The federal appeals courts haven't been kind recently to U.S. district judges dolling out class action settlement funds to charities when payments to some or all of the plaintiffs aren't feasible. In the last seven months, both the 5th and 9th Circuit Courts of Appeals have taken issue with distributing funds to libraries, bar organizations, or other charities not related to the underlying case.

But in the case of an $11.4 million award to a Harvard cancer research center, a three-judge panel of the 1st Circuit Court of Appeals ruled Monday that Harvard can keep the money left over from TAP Pharmaceutical's $150 million class action settlement. TAP was targeted after pleading guilty in connection with fraudulently pricing and marketing the prostate cancer drug Lupron. The settlement had called for $40 million to go to consumers, yet millions went unclaimed by Lupron users.

The appeals court found U.S. District Judge Richard Stearns of Boston did not abuse his discretion in directing the money to Harvard. But the appellate court expressed "concerns" about the idea of giving trial judges discretion by litigants to decide how to distribute unclaimed funds.

"It is true that the court attempted to compensate for the parties' failure to designate recipients in the agreement by taking proposals from the parties and fully involving them in the selection process," wrote Chief Judge Sandra Lynch for a panel that also included Judge Kermit Lipez and former U.S. Supreme Court Justice David Souter sitting by designation. "But the choice would have been better made by the parties initially and then tested by the court, against the principles we have identified."

The decision was the latest to look at how so-called cy pres awards are distributed. In September, the 5th Circuit nixed an $830,000 cy pres award of funds left over from a $41 million settlement with the chemical company Elf Atochem. The 9th Circuit followed the trend in November by rejecting a settlement with AOL that included $110,000 in cy pres awards to charities that the appeals court said did not "address the objectives of the underlying statutes."

Lawyers for both the AOL and Elf Atochem objectors said the 1st Circuit's opinion is actually consistent with the logic in their cases, even though the court upheld the cy pres award. Ted Frank of the Center for Class Action Fairness, who represented the AOL objector, called the 1st Circuit decision a "landmark" on his blog, and said in an email to On The Case that he plans to cite it in an upcoming 3rd Circuit cy pres challenge. Brian Wolfman, a professor at Georgetown University Law Center who represented the Elf Atochem objector, said the 1st Circuit ruling is a "solid opinion that sets out basic principles and applies them in a factual context that's not terribly controversial."

Why do Frank and Wolfman like the ruling? For one thing, class members won almost twice their damages in the settlement, so distributing leftover funds wouldn't preclude the class from full recovery. (That wasn't true in their cases, Wolfman said.) Judge Lynch wrote that allowing for a windfall for the 11,000 claimants in the TAP Pharmaceutical litigation could also create a bad incentive for victims to sue in cases where the odds are high that many plaintiffs' wouldn't make claims. (In the case of Lupron, many class members died of prostate cancer.)

Wolfman also noted the TAP cy pres award was going to an appropriate charity, unlike the awards in the AOL and Elf Atochem cases. The 5th and 9th Circuits said the cy pres funds shouldn't go to charities with little relevance to the classes, such as a bar organization or a scholarship fund. By contrast, the Dana-Farber/Harvard Cancer Center said it intended to use the award to fund "the treatment of prostate cancer and other Lupron-treatable diseases and conditions."

"I think what the court had here was an excellent example where a cy pres award can be used for a truly laudable goal for funding fundamental research that is in the interest of Lupron victims," said TAP Pharmaceutical class counsel Thomas Sobol of Hagens Berman Sobol Shapiro.

Objectors counsel Donald Haviland of Haviland Hughes said his clients plan to petition the U.S. Supreme Court for certiorari. Unlike Wolfman and Frank, Haviland contended the decision "goes against the 5th Circuit and 9th Circuit (rulings) that class members should be fully compensated."

Neither Dana-Farber counsel Martin Fantozzi of Goulston & Storrs or spokespeople for the center responded to requests for comment.

(Reporting by Nate Raymond)

Follow us on Twitter: @nateraymond,@ReutersLegal 


Register or log in to comment.

© 2013 Thomson Reuters